VALPROIC ACID PHARMACOKINETICS ARE NOT ALTERED FOLLOWING CYP2D6 INHIBITION WITH QUINIDINE

被引：0
|
作者：
BOTTORFF, MB
DEAN, S
BENNETT, JA
KECK, PE
机构：
[1] UNIV CINCINNATI,DIV PHARMACOTHERAPY,CINCINNATI,OH 45221
[2] UNIV CINCINNATI,DEPT PSYCHIAT,CINCINNATI,OH 45221
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1993年 / 53卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [1] QSAR studies of quinidine inhibition of CYP2D6
    Hutzler, JM
    Wienkers, LC
    DRUG METABOLISM REVIEWS, 2002, 34 : 172 - 172
  • [2] Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol
    Bramer, SL
    Suri, A
    CLINICAL PHARMACOKINETICS, 1999, 37 (Suppl 2) : 41 - 51
  • [3] Inhibition of CYP2D6 by Quinidine and its Effects on the Metabolism of Cilostazol
    Steven L. Bramer
    Ajit Suri
    Clinical Pharmacokinetics, 1999, 37 : 41 - 51
  • [4] Insight into the effects of chiral isomers quinidine and quinine on CYP2D6 inhibition
    Ai, Chunzhi
    Li, Yan
    Wang, Yonghua
    Chen, Yadong
    Yang, Ling
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 803 - 806
  • [5] Differentially altered metabolism and inhibition of CYP2D6*10.
    Ramamoorthy, Y
    Suh, N
    Tyndale, RF
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 121 - 121
  • [6] Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
    Belle, DJ
    Ernest, CS
    Sauer, JM
    Smith, BR
    Thomasson, HR
    Witcher, JW
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1219 - 1227
  • [7] Pharmacokinetics of Oxycodone in Extensive and Poor Metabolizers of CYP2D6 during Cotreatment with Placebo or Quinidine
    Sirhan-Daneau, Andrea
    Michaud, Veronique
    St-Onge, Maude
    Turgeon, Jacques
    DRUG METABOLISM REVIEWS, 2009, 41 : 81 - 82
  • [8] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [9] CYP2D6 and chlorpheniramine pharmacokinetics.
    Yasuda, SU
    Zannikos, P
    Young, AE
    Fried, KM
    Wainer, JW
    Woosley, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P7 - P7
  • [10] Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
    Oliver Kummer
    Felix Hammann
    Claudine Moser
    Olivier Schaller
    Jürgen Drewe
    Stephan Krähenbühl
    European Journal of Clinical Pharmacology, 2011, 67 : 63 - 71
12345